How chemical restraint
is regulated.
Three documents do most of the work when a Behaviour Support Practitioner is deciding whether a psychotropic prescription counts as a regulated restrictive practice: the NDIS Commission's operational framework, the NDIS Act 2013 that empowers it, and the ACSQHC clinical-quality standard that sits alongside it. Every substance page on this site links here rather than restating these paragraphs.
NDIS Quality and Safeguards Commission
The Commission is the Commonwealth regulator for NDIS-registered providers. Its Regulated Restrictive Practices framework defines the five categories of restrictive practice that require authorisation and reporting — chemical, mechanical, environmental, physical, and seclusion — and sets the operational obligations on providers and Behaviour Support Practitioners.
Chemical restraint specifically means the use of medication or a chemical substance for the primary purpose of influencing a person's behaviour, rather than for the treatment of a diagnosed mental or physical illness. That definition — and the authorisation pathway that follows from it — is the spine of every jurisdictional overlay further down a substance page.
National Disability Insurance Scheme Act 2013
The parent statute. The Act establishes the NDIS Quality and Safeguards Commission, defines the Commissioner's functions, and provides the legislative basis for the rules that operationalise the regulated-restrictive-practices framework — including the NDIS (Restrictive Practices and Behaviour Support) Rules 2018.
For practitioners, the Act is rarely the working document; the Rules and Commission guidance are. It's cited here as the statutory anchor — the source of authority that the operational framework above is exercised under.
ACSQHC Psychotropic Medicines Clinical Care Standard
The Australian Commission on Safety and Quality in Health Care publishes the Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard (2024). Eight quality statements set the clinical bar for psychotropic prescribing in people with cognitive disability: comprehensive assessment, trial of non-pharmacological strategies first, informed consent, monitoring, and time-limited prescribing.
The Standard is not legislation. It carries weight through clinical governance and accreditation pathways, and complements — rather than overlaps with — the NDIS Commission's authorisation framework. A prescription can be clinically appropriate under this Standard and still trigger regulated-restrictive-practice obligations under the NDIS Rules.
What the Behaviour Support Practitioner is doing here
Read the perspective that fits why you're here.
For family members and guardians
When a Behaviour Support Practitioner reviews a psychotropic medication your relative is taking, they aren't second- guessing the prescriber's clinical decision. They're checking a separate question: whether, given the documented purpose of the medication, it counts as a regulated restrictive practice under the NDIS framework — and if so, whether the authorisation, behaviour support plan, and reduction strategy required by the framework are all in place. The medication keeps doing what the prescriber prescribed it for; the BSP is making sure the surrounding paperwork and safeguards exist.
For prescribers
A BSP reviewing a participant's psychotropic is checking two things at once: that the prescription is clinically sound under the ACSQHC clinical care standard (assessment, non-pharmacological trial first, monitoring), and that — given the documented purpose — it does or doesn't fall into the NDIS Commission's definition of chemical restraint. The BSP is not authorised to change a prescription; the goal is to raise the regulated-practice question early so the prescriber, BSP, and authorising body can coordinate rather than discover the issue at audit.
Aged-care equivalent
The parallel restrictive-practices regime for aged-care providers — same reasoning structure, different statute and regulator.
The reasoning structure on every substance page is largely transferable to the parallel aged-care restrictive-practices framework administered by the Aged Care Quality and Safety Commission. The Commonwealth Aged Care Act governs in place of the NDIS Rules; the medication-context analysis is otherwise the same.